An active pharmaceutical ingredient (API) facility of Biocon in Bengaluru has been issued four observations by the U.S. Food and Drug Administration post an inspection.
“The U.S. FDA conducted a surveillance inspection of our API facility (Site 2) located in Bengaluru from September 23-27. Four observations were cited at the end of the inspection, which the company will be addressing within the stipulated time. The company does not foresee any impact on the business,” Biocon said in a filing on Saturday.
Published – September 28, 2024 08:02 pm IST
Denial of responsibility! Pioneer Newz is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.
